

# People

## Mark Tepper appointed at Arradial

Arradial (<http://www.arradial.com>) has appointed Mark A. Tepper as CEO, President and Director. Before joining the company, Tepper served as Vice President Research and Operations at the Serono Pharmaceutical Research Institute where he was a member of the senior research management team and headed the Lead Discovery efforts. He also served as Worldwide Project Leader for the Infercept project that entered Phase 1 clinical trials in January 2001 for multiple sclerosis. In addition, Tepper has held leadership roles at Bristol-Myers Squibb and University of Massachusetts Medical School.

'Dr Tepper is the ideal person to lead the development and commercialization of Arradial's proprietary platforms,' commented Stella M. Sung, Chairman of Arradial's Board of Directors, 'Dr Tepper has over 24 years of experience in biomedical research and spent the last fourteen years leading small-molecule and protein therapeutic discovery and early development projects in large pharmaceutical and biotechnology companies. Dr Tepper's vision and ability to anticipate technological breakthroughs in the ever-changing drug discovery landscape will provide critical advantages to Arradial.'

## Galapagos gets new Chief Scientific Officer

Robin Brown has been appointed as Chief Scientific Officer at Galapagos Genomics (<http://www.galapagosgenomics.com>). He will be responsible for directing the R&D programs, focussed on target discovery and validation. The appointment comes at a time when Galapagos is entering a new phase in its development, in which it will validate proprietary drug targets and initiate drug discovery activities.

Before joining Galapagos, Brown held the position of Chief Scientific Officer at Devgen in Belgium. He has also worked at GlaxoWellcome as head of the Cell and Molecular Biology Department at the Stevenage research campus in the UK. Onno van de Stolpe, CEO of Galapagos, said, 'Robin brings invaluable pharma experience to the organization that will be essential for building a successful company that uses genomics technologies to improve the productivity of the drug-discovery process.'

## New senior appointment at Mojave

Mojave Therapeutics (<http://www.mojave-therapeutics.com>), a company specializing in the development of immunotherapies based on heat-shock protein, has announced the appointment of Brian H. Barber to the newly created role of Chief Scientific Officer and Senior Vice President. Barber joins the company from Aventis Pasteur, where he held the position of Assistant Vice President for Immunology. Before this, Barber was a Professor in the Department of Immunology, Faculty of Medicine at the University of Toronto for 20 years. Timothy Cooke, CEO of Mojave Therapeutics, commented: 'Dr Barber is an internationally recognized immunologist who combines a distinguished academic career with significant industrial experience in the development of therapeutic vaccines for cancer and chronic viral diseases.'

## Peter Fellner to stand down at Celltech

Celltech (<http://www.celltech.co.uk>), Britain's largest biotech company, will soon be looking for a new Chief Executive. Peter Fellner, who has held the position for 12 years, will become Chairman, possibly in the autumn 2002. Celltech insiders say, 'We want to be able to identify the new Chief Executive before he moves.' The leading internal candidate for the vacancy is Peter Allen; outside candidates will also be examined.

## Veteran of biotechnology industry joins Sofinnova Ventures

Harry E. Selick is to join Sofinnova Ventures as a Venture Partner. Sofinnova is a venture firm investing in early-stage information technology and life science companies, including AlgoRX, Actelion, David Pharmaceuticals, Exhale Therapeutics and KaloBios. Before coming to Sofinnova, Selick was co-founder, President and CEO of Camitro, establishing two corporate sites in California and the UK. Before that position, he was a Senior Scientist at Anergen, and a Staff Scientist at Protein Design Labs, where he pioneered work on fully humanized antibodies. Michael Powell, a Managing Director of Sofinnova, welcomed Selick to the company: 'His scientific expertise will enable him to distinguish the most

promising biotechnology companies for Sofinnova to invest in, and his strong operational background will make him perfectly suited to take on interim management roles for our young start-ups.'

## New appointments to Entomed's Scientific Advisory Board

Entomed (<http://www.entomed.se>), which develops novel drugs derived from insects, has announced the nomination of two new members to its Scientific Advisory Board. Jean-Claude Braekman joins the board as Director of the Department of Organic Chemistry at the Université Libre de Bruxelles, and Luis Serrano brings his experience as Programme Coordinator Structural and Computational Biology at the European Molecular Biology Laboratory.

Braekman has 30 years of experience in academic research, particularly in the study of bioactive secondary metabolites from insects, marine invertebrates and African plants. Serrano has 20 years experience in biochemical research and is a specialist in the study of microtubule proteins. Mario Thomas, CEO of Entomed, commented: 'Jean-Claude Braekman will provide us with insights which will enable us to extend our capabilities in the area of insect-derived therapeutic small molecules discovery, while Luis's expertise in structural and computational protein chemistry will assist us to further develop our peptides drug discovery platform.'

## New Director for the Bill and Melinda Gates Foundation

Richard D. Klausner has been named Executive Director of the Bill and Melinda Gates Foundation's global health program. Klausner is the former Director of the National Cancer Institute, one of the world's largest research and health agencies. He has also recently served as Senior Fellow and Special Advisor to the Presidents of the National Academics for Counter Terrorism and Liaison to the White House. William H. Gates III, co-founder of the foundation, commented, 'With nearly three decades of medical and scientific leadership, Dr Klausner brings clear vision, a dedication to public health and proven results. He is a visionary who knows how to translate science into action.'

People was written by  
*Matt Brown*